focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 488.00
Bid: 490.00
Ask: 495.00
Change: 12.00 (2.52%)
Spread: 5.00 (1.02%)
Open: 478.00
High: 491.00
Low: 474.00
Prev. Close: 476.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

High-performance foam in medical facility doors

27 Apr 2023 07:00

RNS Number : 6037X
Zotefoams PLC
27 April 2023
 

27 April 2023

Zotefoams plc

("Zotefoams" or "Group")

 

Agreement to supply high-performance foam for use in medical facility doors

Zotefoams, a world leader in cellular materials technology, is pleased to announce an agreement with Kennon Products (Wyoming, USA) to supply ZOTEK® F high-performance foam for use in Kennon's newest ligature-resistant patient safety door, broadening the scope of application for this material. So-called breakaway doors are used in medical facilities to protect vulnerable patients from self-harm while affording privacy.

Produced exclusively by Zotefoams and manufactured from PVDF (polyvinylidene fluoride), ZOTEK F is best-known as a disruptive material that has enabled airframe manufacturers and airlines to reduce carbon consumption by shedding significant weight from aircraft interiors. Equally important are the safety credentials of the material: PVDF is inherently inert, and Zotefoams' proprietary method of foam manufacture does not affect that essential purity. Accordingly, ZOTEK F achieves the highest ratings for its Fire, Smoke and Toxicity (FST) properties and also exhibits excellent resistance to mould and bacteria growth.

Safety is the foremost consideration in the design of the Kennon Door 2.0. The softness of ZOTEK F and its light weight combine with breakaway magnetic hinges to save lives, as do its resistance to flame and - in the event of ignition - low smoke output. The durable design of the door also enhances the look of any facility.

Kennon achieved its primary objective, that of developing a door that achieves the USA's new National Fire Protection Association NFPA-286 certification, which is required for facility operators wishing to meet certain fire prevention guidelines.

"The unique properties of ZOTEK F foam are a key reason for our anti-ligature doors meeting the NFPA-286 standard," said Kennon CEO, Joe Wright. "Our partnership with Zotefoams has been a mutual success and together we're helping to save lives in behavioural health hospitals."

David Stirling, Zotefoams Group CEO, commented, "We were pleased to work closely with Kennon on this project, selecting and testing various ZOTEK F materials, while providing support and insight based on our previous experience of aviation applications and flame testing.

"This application has produced another 'first' for ZOTEK F and demonstrates the potential of the material to deliver benefits well beyond its current core markets of aviation and aerospace."

* ENDS *

 

 

Enquiries:

 

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAIFMFTMTATBBJ
Date   Source Headline
19th Jul 20231:29 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSJoint development agreement for ReZorce®
12th Jul 202311:01 amRNSNotification Of Transactions Of Directors/PDMRs
10th Jul 20237:00 amRNSNotice of results and investor presentation
22nd Jun 20232:20 pmRNSHolding(s) in Company
20th Jun 202310:16 amRNSNotification Of Transactions Of Directors/PDMRs
14th Jun 20237:00 amRNSHolding(s) in Company
13th Jun 20232:55 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
6th Jun 20231:34 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Jun 20238:00 amRNSNike Exclusivity Agreement Extension
24th May 202311:40 amRNSResult of the 2023 Annual General Meeting
24th May 20237:00 amRNSTrading Update and Chair Succession
12th May 202310:42 amRNSNotification Of Transactions Of Directors/PDMRs
27th Apr 20237:00 amRNSHigh-performance foam in medical facility doors
26th Apr 20235:44 pmRNSNotification Of Transactions Of Directors/PDMRs
26th Apr 20233:39 pmRNSNotification Of Transactions Of Directors/PDMRs
24th Apr 20235:50 pmRNSReplacement Notice Transactions Of Directors/PDMRs
24th Apr 20234:42 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Apr 20237:00 amRNS2022 Annual Report and Notice of the 2023 AGM
19th Apr 20234:41 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Apr 20231:18 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Mar 20234:35 pmRNSPrice Monitoring Extension
22nd Mar 20231:30 pmRNSHolding(s) in Company
21st Mar 20234:10 pmRNSNotification Of Transactions Of Directors/PDMRs
21st Mar 20234:09 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20234:58 pmRNSHolding(s) in Company
14th Mar 20233:09 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Feb 20237:00 amRNSAward of AA ESG Ratings assessment
15th Feb 20237:00 amRNSNotice of Results
14th Feb 20233:34 pmRNSNotification Of Transactions Of Directors/PDMRs
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20237:00 amRNSFull Year Trading Update
17th Jan 20237:00 amRNSChair Succession
12th Jan 202311:18 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20227:00 amRNSTrading Update
13th Dec 20224:03 pmRNSNotification Of Transactions Of Directors/PDMRs
6th Dec 20229:42 amRNSNotification Of Transactions Of Directors/PDMRs
5th Dec 202211:34 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 202211:27 amRNSNotification Of Transactions Of Directors/PDMRs
14th Nov 20227:00 amRNSAppointment of Joint Broker
9th Nov 20227:00 amRNSAcquisition of the assets and IP of Refour ApS
17th Oct 202211:31 amRNSNotification Of Transactions Of Directors/PDMRs
13th Oct 20227:00 amRNSTrading Update
12th Oct 20224:02 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20224:41 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSIndependent Life Cycle Assessment of ReZorce
13th Sep 20223:43 pmRNSDirector/PDMR Shareholding
23rd Aug 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.